Nucleophosmin mutations in hematological malignancies - review.
- Author:
Zhan-Peng LUO
1
;
Ling ZHANG
Author Information
1. Department of Clinical Hematology, Faculty of Laboratory Medicine, Chongqing University of Medical Sciences, Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Chongqing 400016, China.
- Publication Type:Journal Article
- MeSH:
Cell Nucleolus;
metabolism;
Hematologic Neoplasms;
genetics;
pathology;
Humans;
Mutation;
Nuclear Proteins;
genetics;
fms-Like Tyrosine Kinase 3;
genetics
- From:
Journal of Experimental Hematology
2007;15(3):662-666
- CountryChina
- Language:Chinese
-
Abstract:
Nucleophosmin (NPM) is a protein that shuttles between the nucleus, nucleoplasm and cytoplasm. NPM gene mutations and aberrant cytoplasmic NPM localization have been recently described in acute myelogenous leukemia (AML) with normal karyotype and in a few myelodysplastic syndromes. Expression of NPM mutant reduces the ability of Arf to initiate a p53 response and to induce cell cycle arrest. Clinical research has revealed that NPM mutations are relative to prognosis and can be used to monitor and quantify minimal residual disease (MRD) in AML patients with normal karyotype, therefore, these findings indicate that nucleophosmin mutations might contribute to illustration of myeloid leukemogenesis. In this paper, the research progress of nucleophosmin mutations in haematological malignancies was reviewed.
